The year 2019 kicked off with the biopharma industry’s largest acquisition proposal ever: Bristol-Myers Squibb unveiled it would buy Celgene in a cash and stock deal valued at $74 billion.
New king Humira, fast-growing Revlimid, Roche's under-attack cancer cash cows. Here are the biopharma's most successful drugs by lifetime sales till 2024.
